東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Tumor immune escape: Molecular mecha...

Chang, Chien-Chung.

FindBook

Google Book

Amazon

博客來

Tumor immune escape: Molecular mechanisms and counteracting strategies.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Tumor immune escape: Molecular mechanisms and counteracting strategies./
作者:	Chang, Chien-Chung.
面頁冊數:	276 p.
附註:	Source: Dissertation Abstracts International, Volume: 66-06, Section: B, page: 3040.
Contained By:	Dissertation Abstracts International66-06B.
標題:	Health Sciences, Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3179461
ISBN:	0542195348

Tumor immune escape: Molecular mechanisms and counteracting strategies.
Chang, Chien-Chung.

Tumor immune escape: Molecular mechanisms and counteracting strategies. - 276 p.

Source: Dissertation Abstracts International, Volume: 66-06, Section: B, page: 3040.

Thesis (Ph.D.)--State University of New York at Buffalo, 2005.

Changes in HLA class I antigen and NK cell-activating ligand expression have been identified in malignant lesions. These changes are believed to play a major role in the clinical course of the disease since both HLA class I antigens and NK cell-activating ligands are critical to the interaction between tumor cells and components of both innate and adaptive immune systems. In this study, novel molecular mechanisms underlying HLA class I antigen abnormalities have been identified in melanoma cells derived from malignant melanoma lesions. They include multiple hot-spot CT deletions in the beta2 m gene, selective HLA-A2 allospecificity loss, and antigen processing machinery component downregulation, which underlie a HLA class I antigen loss phenotype, as well as single amino acid substitution-carrying, loss-of-function beta 2m and combined germline/somatic tapasin gene mutations along with selective epigenetic inactivation of HLA-A locus IFN-gamma responsiveness, which underlie a HLA class I antigen downregulaiton phenotype. The role of NK cell-activating ligand changes in melanoma immune escape is indicated by the markedly reduced sensitivity to NK cell-mediated lysis in vitro of two of four HLA class I- melanoma cell lines because of their lack of expression of MICA, a ligand for the NKG2D activating receptor. These MHC defects have potential negative impact on both cytotoxic T lymphocyte- and NK cell-mediated anti-tumor responses and thus prompted the development of active specific cancer immunotherapy targeting non-MHC molecules. To this end, the three-dimensional structural basis of tumor antigen mimicry by an anti-idiotypic (id) antibody has been elucidated at the atomic level in the high molecular weight-melanoma associated antigen (HMW-MAA) system. A single complementarity-determining region loop of anti-id antibody MK2-23, which carries the internal image of the nominal HMW-MAA epitope, represents a useful system to investigate which extent of antigen mimicry would maximize the immunogenicity of an antigen mimic. Taken together, the results of my study advance our understanding of the mechanisms underlying the lack of immune control of clinically evident tumors and contribute to the development of alternative cancer immunotherapeutic strategies.

ISBN: 0542195348Subjects--Topical Terms:

1017716
Health Sciences, Immunology.

Tumor immune escape: Molecular mechanisms and counteracting strategies.
LDR:03216nmm 2200289 4500 001 1815423
005 20060710075956.5
008 130610s2005 eng d
020 $a 0542195348
035 $a (UnM)AAI3179461
035 $a AAI3179461
040 $a UnM $c UnM
100 1 $a Chang, Chien-Chung. $3 1904846
245 1 0 $a Tumor immune escape: Molecular mechanisms and counteracting strategies.
300 $a 276 p.
500 $a Source: Dissertation Abstracts International, Volume: 66-06, Section: B, page: 3040.
500 $a Major Professor: Soldano Ferrone.
502 $a Thesis (Ph.D.)--State University of New York at Buffalo, 2005.
520 $a Changes in HLA class I antigen and NK cell-activating ligand expression have been identified in malignant lesions. These changes are believed to play a major role in the clinical course of the disease since both HLA class I antigens and NK cell-activating ligands are critical to the interaction between tumor cells and components of both innate and adaptive immune systems. In this study, novel molecular mechanisms underlying HLA class I antigen abnormalities have been identified in melanoma cells derived from malignant melanoma lesions. They include multiple hot-spot CT deletions in the beta2 m gene, selective HLA-A2 allospecificity loss, and antigen processing machinery component downregulation, which underlie a HLA class I antigen loss phenotype, as well as single amino acid substitution-carrying, loss-of-function beta 2m and combined germline/somatic tapasin gene mutations along with selective epigenetic inactivation of HLA-A locus IFN-gamma responsiveness, which underlie a HLA class I antigen downregulaiton phenotype. The role of NK cell-activating ligand changes in melanoma immune escape is indicated by the markedly reduced sensitivity to NK cell-mediated lysis in vitro of two of four HLA class I- melanoma cell lines because of their lack of expression of MICA, a ligand for the NKG2D activating receptor. These MHC defects have potential negative impact on both cytotoxic T lymphocyte- and NK cell-mediated anti-tumor responses and thus prompted the development of active specific cancer immunotherapy targeting non-MHC molecules. To this end, the three-dimensional structural basis of tumor antigen mimicry by an anti-idiotypic (id) antibody has been elucidated at the atomic level in the high molecular weight-melanoma associated antigen (HMW-MAA) system. A single complementarity-determining region loop of anti-id antibody MK2-23, which carries the internal image of the nominal HMW-MAA epitope, represents a useful system to investigate which extent of antigen mimicry would maximize the immunogenicity of an antigen mimic. Taken together, the results of my study advance our understanding of the mechanisms underlying the lack of immune control of clinically evident tumors and contribute to the development of alternative cancer immunotherapeutic strategies.
590 $a School code: 0656.
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Chemistry, Biochemistry. $3 1017722
690 $a 0982
690 $a 0307
690 $a 0487
710 2 0 $a State University of New York at Buffalo. $3 1017814
773 0 $t Dissertation Abstracts International $g 66-06B.
790 1 0 $a Ferrone, Soldano, $e advisor
790 $a 0656
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3179461